Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
- Welzel, Tania M.
- Nelson, David R.
- Morelli, Giuseppe
- Di Bisceglie, Adrian
- Reddy, Rajender K.
- Kuo, Alexander
- Lim, Joseph K.
- Darling, Jama
- Pockros, Paul
- Galati, Joseph S.
- Frazier, Lynn M.
- Alqahtani, Saleh
- Sulkowski, Mark S.
- Vainorius, Monika
- Akushevich, Lucy
- Fried, Michael W.
- Zeuzem, Stefan
DOIAbstract
Due to a high efficacy in clinical trials, sofosbuvir (SOF) and ribavirin (RBV) for 12 or 16 weeks is recommended for treatment of patients with HCV genotype (GT) 2 infection. We investigated safety and effectiveness of these regimens for GT2 in HCV-TARGET participants
Add to ORKG